Premium
Sulfated polymannuroguluronate, a novel anti‐acquired immune deficiency syndrome drug candidate, blocks neuroinflammatory signalling by targeting the transactivator of transcription (Tat) protein
Author(s) -
Hui Bin,
Xia Wei,
Li Jing,
Wang Limei,
Ai Jing,
Geng Meiyu
Publication year - 2006
Publication title -
journal of neurochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.75
H-Index - 229
eISSN - 1471-4159
pISSN - 0022-3042
DOI - 10.1111/j.1471-4159.2006.03698.x
Subject(s) - transactivation , neuroinflammation , biology , tumor necrosis factor alpha , immune system , protein kinase c , kinase , microbiology and biotechnology , neurotoxicity , pharmacology , transcription factor , signal transduction , immunology , inflammation , cancer research , chemistry , medicine , biochemistry , gene , toxicity
Impaired inflammatory functions may be critical factors in the mechanisms of severe CNS disorders classified as the human immunodeficiency virus‐1 (HIV‐1)‐associated dementia (HAD). Evidence indicates that a viral gene product, the transactivator of transcription protein (Tat), can markedly contribute to these events. We herein report that sulfated polymannuroguluronate (SPMG), a novel anti‐acquired immunodeficiency syndrome drug candidate now in a phase II clinical trial, significantly reversed Tat‐induced release of pro‐inflammatory cytokines [tumour necrosis factor (TNF)‐α, interleukin (IL)‐1β) and IL‐6] and dose dependently decreased the accumulation of reactive oxygen species and nitric oxide in THP‐1 cells. Furthermore, SPMG potently arrested Tat‐triggered protein kinase C (PKC)‐dependent PKC‐μ activation, and blocked the downstream extracellular‐signal regulated kinase 1/2‐ and c‐jun amino‐terminal kinase‐mediated signalling pathways. These molecular mechanisms could be attributed to the fact that SPMG preferentially bound to the basic domain (amino acids 47–57) of the Tat protein with high affinity ( K D ≈ 8.69 × 10 −10 m ), leading to abrogation of Tat‐mediated neuroinflammation and neurotoxicity. These data demonstrate that SPMG might serve as a valuable therapeutic intervention for Tat‐induced profound pro‐inflammatory effects in the brain, and subsequent pathologic events of HAD.